Can longitudinal measures of plasma biomarkers track disease progression in early Alzheimer´s Disease?

Abstract

Background: Blood based biomarkers of Alzheimer´s disease (AD) that exhibit a high degree of change over time and are associated with deterioration in cognitive performance and atrophy could be useful in clinical trials to monitor treatment responses.

The paper